**Abstract**

**Background:** Mood and anxiety disorders are the leading causes of disability in established market economies such as in Canada. Current anxiolytic drugs have undesirable side effects. Thus better treatments are needed. Existing antidepressants with anxiolytic effects have been shown to reduce the level of G9a, a histone methyltransferase that methylates lysine 9 of histone H3 (H3K9). The methylation status of H3K9 plays an important role in mediating epigenetic responses to environmental stress. Thus, we reason that deliberately targeting G9a may be an effective strategy to discover new anti-anxiety medications.

**Hypothesis:** We hypothesize that the G9a inhibitors UNC0642 and A-366 will have anxiolytic-like effects in established animal models of anxiety.

**Method:** C57BL/6 mice were treated chronically (14 days) with 1mg/kg, 2mg/kg or 5mg/kg of UNC0642 or A-366. The anxiolytic-like effects of UNC0642 and A-366 on mouse behaviour were measured in the elevated zero maze (EZM), the marble burying test (MB) and on novelty suppressed feeding (NSF).

**Results:** Chronic treatment of A-366 increased the amount of time mice spent in the open arm of the EZM, decreased the number of marbles buried and decreased latency to eat in the NSF test. Chronic treatment of UNC0642 increased the amount of time mice spent in the open arms of the EZM but did not affect MB or NSF behaviours.

**Conclusion:** UNC0642 and A-366 showed dose-dependent anxiolytic-like effects on mouse behaviour with chronic treatment. The anxiolytic-like effect was likely due to G9a inhibition, given the distinct chemical structures of the two G9a inhibitors. Further experiments are needed to examine the underlying molecular and transcriptomic changes associated with behavioral changes.

**Significance:** These data increase knowledge of novel molecular pathways that regulate symptoms of human psychiatric disorders, and will lay the foundation for further efforts to discover new and better treatments for these important illnesses.
